Compare Dicks Sporting Goods Inc (DKS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Neurocrine Biosciences Inc — how do they compare? Dicks Sporting Goods Inc trades at $134.34 (market cap $13.26B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Dicks Sporting Goods Inc and Neurocrine Biosciences Inc are close in size by market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DKS | NBIX | |
|---|---|---|
Market Cap | $13.26B | $14.36B |
Volume | 2,292,035 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $185.50 |
52-Week Low | $121.15 | $123.10 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $20.31B | $14.37B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, with a bearish technical signal from moving averages and oscillators. The company shows solid profitability with an 18.47% ROE and a net income margin of 3.97%, though recent earnings missed expectations in Q2 2026. Revenue grew to $13.44B in 2025, but profit margins are projected to compress in 2026. A securities class action lawsuit filed for the period September 2025 to August 2026 adds legal overhang.
The stock presents a mixed outlook; strong analyst consensus with a $153.30 price target suggests 17% upside, supported by a reasonable P/E of 14.48. However, near-term risks include the class action litigation, technical bearishness, and margin pressure. The dividend increase to $1.25 signals confidence, but investors must weigh legal and operational headwinds against valuation appeal.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
